Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis

An open-label, phase II study demonstrated that a ruxolitinib dose-escalation approach (10 mg BID plus incremental increases of 5 mg BID at weeks 12 and 18, up to 20 mg BID) may help reduce the severity of anemia among patients with myelofibrosis.

 Oncology Nurse Advisor

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.